4,4'-(1,4-piperazinediyl)bisbenzenecarboximidamide dihydrochloride | 123885-92-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4,4'-(1,4-piperazinediyl)bisbenzenecarboximidamide dihydrochloride
• 英文别名: N,N'-bis(4-amidinophenyl)piperazine dihydrochloride；4,4-Piperazinediyl)bisbenzenecarboximidamide, dihydrochloride；4-[4-(4-carbamimidoylphenyl)piperazin-1-yl]benzenecarboximidamide;hydrochloride
• CAS: 123885-92-7
• 化学式: C₁₈H₂₂N₆*2ClH
• 分子量: 395.335
• InChiKey: PGIPCFMMASQELS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.0
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  106
• 氢给体数：
  5
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4,4'-(1,4-piperazinediyl)bisbenzonitrile 在 盐酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 168.0h， 生成 4,4'-(1,4-piperazinediyl)bisbenzenecarboximidamide dihydrochloride
  参考文献：
  名称：

  Vanden Eynde, Jean Jacques; Mayence, Annie; Lecour Jr., Louis, Medicinal Chemistry Research, 2003, vol. 12, # 8, p. 401 - 414

  摘要：

  DOI：

文献信息

• 1,4–Diarylpiperazines and analogs as anti-tubercular agents: Synthesis and biological evaluation
  作者：D. Forge、D. Cappoen、J. Laurent、D. Stanicki、A. Mayence、T.L. Huang、L. Verschaeve、K. Huygen、J.J. Vanden Eynde

  DOI：10.1016/j.ejmech.2011.12.035

  日期：2012.3

  bacillary persistence and human immunodeficiency virus (HIV) co-infection hamper current drug treatment to completely cure the infection, generating a constant demand for novel drug candidates to tackle these problems. A small library of novel heterocyclic compounds was screened in a rapid luminometric in vitro assay against the laboratory M.tb. strain H37Rv. A group of amidines was found to have the highest

  尽管现代化学疗法在抗击结核病方面取得了进展，但致病菌结核分枝杆菌（M.tb.）仍未根除。细菌对抗分枝杆菌药的耐药性，细菌持续性和人类免疫缺陷病毒（HIV）共同感染阻碍了目前的药物治疗以完全治愈感染，从而产生了不断寻求新的候选药物来解决这些问题的需求。 在针对实验室M.tb的快速光度体外测定中筛选了一个小的新型杂环化合物文库。H37Rv株。发现一组of具有最高的效力，并进一步评估了其对C3A肝细胞的急性毒性。接下来，评估了最有前途的化合物对多药耐药临床分离株的活性。还测试了idine的组杀死细胞内M.tb的能力。驻留在小鼠J774A.1巨噬细胞中。最后，我们报告了化合物的结构差异与其抗分枝杆菌活性之间的相关性。
• Synthesis and anti-Pneumocystis carinii activity of conformationally restricted analogues of pentamidine
  作者：Bin Tao、Tien L Huang、Qian Zhang、Latasha Jackson、Sherry F Queener、Isaac O Donkor

  DOI：10.1016/s0223-5234(99)80102-0

  日期：1999.6

  A series of conformationally restricted analogues of pentamidine in which the flexible central bridge has been replaced by trans-cyclopropyl, phenyl, pyridinyl, piperazinyl or homopiperazinyl groups as conformationally restricted linkers have been synthesized. The anti-Pneumocystis carinii activity of these compounds was evaluated in a cell culture model and the DNA binding affinity was determined by thermal denaturation measurements. At 1 mu M, compounds 2, 3, 5, 7, 9 and pentamidine were highly effective and caused total inhibition of P. carinii growth in culture. At 0.1 mu M, compounds 2, 5, 7 and 10 were more active than pentamidine with N, N'-bis(4-amidinophenyl)piperazine 7 being approximately 15-fold more effective than pentamidine. The most active compounds, 7 and 10, showed strong binding affinities for calf thymus DNA and poly(dA-dT); however, a clear correlation between DNA binding affinity and the in vitro anti-P. carinii activity of these compounds was not observed. The results suggest that the nature of the central Linker influences the biological actions of these compounds. (C) Elsevier, Paris.
• Vanden Eynde, Jean Jacques; Mayence, Annie; Lecour Jr., Louis, Medicinal Chemistry Research, 2003, vol. 12, # 8, p. 401 - 414
  作者：Vanden Eynde, Jean Jacques、Mayence, Annie、Lecour Jr., Louis、Huang, Tien L.

  DOI：——

  日期：——
• Piperazine-linked bisbenzamidines: a novel class of antileishmanial agents
  作者：Annie Mayence、Jean Jacques Vanden Eynde、Louis LeCour、Larry A. Walker、Babu L. Tekwani、Tien L. Huang

  DOI：10.1016/j.ejmech.2004.01.009

  日期：2004.6

  A series of 13 1,4-diarylpiperazines has been prepared, evaluated for antileishmanial activity and their binding affinity to DNA was measured. Among these compounds, 1,4-bis[4-(1H-benzimidazol-2-yl)phenyl]piperazine (14) emerged as the most active compound with an IC50 value of 0.41 muM which is about sevenfold more potent than pentamidine. (C) 2004 Elsevier SAS. All rights reserved.